非抗菌細菌療法市場——技術、市場、戰略和預測
市場調查報告書
商品編碼
1250861

非抗菌細菌療法市場——技術、市場、戰略和預測

Non-Antibiotic Bacterial Therapeutics - Technologies, Markets, Strategies & Forecasts

出版日期: | 出版商: Greystone Research Associates | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告研究了全球非抗菌細菌療法市場,並提供了市場概況以及市場未滿足的需求、技術趨勢、法規和標準以及進入該市場的公司概況。

內容

  • 執行摘要
  • 超越抗生素的細菌治療
  • 執行摘要
  • 市場動態
  • 未滿足的需求
  • 範圍定義
  • 抗生素創新的最新發展和需求
  • 不斷發展的格局
  • 適合年齡的抗生素
  • 技術
  • 抗體
  • 抗生素滅活□
  • 噬菌體
  • 抗菌□
  • 抗菌納米粒子
  • 反義治療/基因沉默
  • 通過膜泵主動流出細菌化合物
  • 多重耐藥外排泵的過度表達
  • 鐵載體
  • 非抗生素微生物療法 - 療法
  • 抗體
  • Aersin (Aridis)
  • Zinprava/bezlotoxumab(默克)
  • 醫療 3902
  • 514G3(X 生物技術)
  • 賴氨酸
  • 噬菌體
  • 抗菌□
  • 防禦素
  • Alenisine(Adenium Biotech)
  • Murepavadin (POL7080)(Polyphor Ltd)
  • Host Directed Therapies
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • 全球市場法規和標準
  • 北美
  • 美國食品藥品監督管理局
  • 美國疾病控制中心
  • 歐洲
  • 歐洲疾病預防控制中心
  • 亞洲
  • 中國疾病預防控制中心
  • 國家疾病控制中心
  • 公司簡介
簡介目錄

‘Non-antibiotic Bacterial Therapeutics ’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for non-antibiotic therapeutic substances that can treat bacterial infections that are resistant to many or most available antibiotics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Novel Approaches Creating New Opportunities in Bacterial Therapeutics

As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials. The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world. Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift in treatment options.

What You Will Learn:

  • What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?
  • What non-antibiotic bacterial therapies are in late stage development, who are the developers, and what indications are they targeting?
  • What are the major factors driving demand for non-antibiotic bacterial treatments?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2028?
  • What are the essential factors, technologies and market development issues for non-antibiotic bacterial therapeutics products?
  • What are the significant economic, technology, and regulatory factors affecting the market for non-antibiotic bacterial therapies.

Table of Contents

  • Executive Summary
  • Bacterial Therapeutics Beyond Antibiotics
  • Executive Summary
  • Market Dynamics
  • The Unmet Need
  • Defining the Scope
  • Recent Developments and the Need for Antibiotic Innovation
  • The Evolving Landscape
  • Age-appropriate Antibiotics
  • Technology
  • Antibodies
  • Antibiotic-deactivating Enzymes
  • Bacteriophages
  • Antimicrobial peptides
  • Antimicrobial Nanoparticles
  • Antisense therapy/gene silencing
  • Active extrusion of bacterial compounds by membrane pumps
  • Overexpression of Multidrug resistance efflux pumps
  • Siderophores
  • Non-antibiotic Microbial Therapeutics - Therapies
  • Antibodies
  • Aerucin (Aridis)
  • Zinplava/Bezlotoxumab (Merck)
  • MEDI 3902 (MedImmune)
  • 514G3 (XBiotech)
  • Lysins
  • Phages
  • Antimicrobial Peptides
  • Defensins
  • Arenicin (Adenium Biotech)
  • Murepavadin (POL7080) (Polyphor Ltd)
  • Host Directed Therapies
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • Global Market Regulations and Standards
  • North America
  • US FDA
  • US Centers for Disease Control
  • Europe
  • European Centre for Disease Prevention and Control
  • Asia
  • Chinese Center for Disease Control and Prevention
  • National Centre for Disease Control (India)
  • Company Profiles